Adazin
Generic name: capsaicin, benzocaine, lidocaine, methyl salicylate
Dosage form: cream
Medically reviewed by Drugs.com. Last updated on Nov 22, 2021.
Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.
On This Page
Rx Only
Description
Adazin is a Capsaicin 0.035% and Benzocaine 2% and Lidocaine 2% and Methyl Salicylate 10% Cream is a topical anesthetic and analgesic indicated for the relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness, and discomfort due to pruritus ani, pruritus vulvae, hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes.
Active Ingredients
Each gram of Adazin Cream contains:
Capsaicin 0.035% (0.35mg) Topical Analgesic
Benzocaine 2% (20mg) Topical Anesthetic
Lidocaine 2% (20mg) Topical Anesthetic
Methyl Salicylate 10% (100mg) Topical Analgesic
Inactive Ingredients
Water, TEA Salicylate, Glycerin, Dimethyl Isosorbide, Glyceryl Stearate, PEG-100 Stearat, PEG-8, Vanillyl Butyl Ether, Cetyl Alcohol, Glyceryl Stearate, Tridecyl Stearate, Neopentyl Glycol Dicaprylate/Dicaprate, Tridecyl Trimellitate, Stearic Acid, Beeswax, Phenoxyethanol, Ethylhexylglycerin, Aloe Vera Gel, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Naproxen, Glucosamine, Sodium Hydroxide, Boswelia Extract, Arnica Oil, MSM, Citric Acid, Lemongrass Oil.
Indications
Anesthetic for relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae, hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes.
Contraindications
Traumatized mucosa, secondary bacterial infection of the area of proposed application and known hypersensitivity to any of the components. Lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.
Warnings
For external use only. Not for ophthalmic use.
